Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Menu
Sign in
Sign in

FDA Lifts Trial Hold on Aprea’s NonHodgkin’s Lymphoma Drug

FDA Lifts Trial Hold on Aprea’s NonHodgkin’s Lymphoma Drug

Aprea Therapeutics has received FDA clearance to continue its eprenetapopt development, with the lifting of a full clinical hold placed last summer on the drug’s nonHodgkin’s lymphoma clinical trial program.

The company didn’t specify why the hold was instituted but said it has addressed the FDA’s concerns. It’s investigating eprenetapopt (APR-246) as add-on therapy in conjunction with azacitidine for myeloid malignancies.

Eprenetapopt, the company’s lead candidate, aims to reactivate the body’s natural tumor suppressor protein on gene p53.

Tumor protein gene p53 (TP53) plays a crucial role in the suppression of cancer growth. The gene also can determine the type of myeloid malignancy a person has, their treatment response and risk of the cancer transforming to acute myeloid leukemia (AML).

December 13, 2021

https://www.fdanews.com/

0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies